Effect of combinational arginase and canavanine treatment on normal human peripheral blood lymphocytes in vitro

Oleh Chen, Bohdanna Kavalets, Marina Barska, Lilianna Lyniv, Olena Vovk, Natalia Sybirna, Oleh Stasyk*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Recombinant human arginase (rhARG)-based therapy to restrict arginine availability for malignant cells is a promising strategy to treat some cancers, including those of hematological origin. In the present study, we evaluated the action of combined rhARG treatment with canavanine (Cav) on proliferative potential and functional state of human peripheral blood lymphocytes (PBL) in vitro. We demonstrated that Cav in 0.1 mM concentration alone had no significant effect on proliferation and functional activity of normal activated PBL. Combined rhARG and Cav treatment inhibited proliferation and slightly promoted apoptosis in activated PBL but did not affect resting cells. However, the action of both drugs affected the ability of T cells for antigen activation. These results are important for further translational research on arginine-deprivation therapy. 2013

Original languageEnglish
Pages (from-to)385-389
Number of pages5
JournalCurrent Issues in Pharmacy and Medical Sciences
Volume26
Issue number4
DOIs
Publication statusPublished - 2013
Externally publishedYes

Keywords

  • Arginase
  • Arginine deprivation
  • Canavanine
  • Peripheral blood lymphocytes

Fingerprint

Dive into the research topics of 'Effect of combinational arginase and canavanine treatment on normal human peripheral blood lymphocytes in vitro'. Together they form a unique fingerprint.

Cite this